Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Status:
Recruiting
Trial end date:
2023-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients
who have already received osilodrostat treatment in a previous Global Novartis-sponsored
trial and who, based on investigators' judgement, will continue benefiting with its
administration.